BACKGROUND: In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was studied in newly diagnosed patients with chronic myeloid leukemia in the HOVON-51 study. DESIGN AND METHODS: Having reported feasibility previously, we hereby report the efficacy of escalated imatinib (200 mg, 400 mg, 600 mg or 800 mg) in combination with two cycles of intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1 to 7) in 162 patients with chronic myeloid leukemia. RESULTS: With a median follow-up of 55 months, the 5-year cumulative incidences of complete cytogenetic response, major molecular response, and complete molecular response were 89%, 71%, and 53%, respectively. A higher Sokal risk score was inversely associated with complete cytogenetic response (hazard ratio of 0.63; 95% confidence interval, 0.50-0.79, P<0.001). A higher dose of imatinib and a higher dose of cytarabine were associated with increased complete molecular response with hazard ratios of 1.60 (95% confidence interval, 0.96-2.68, P=0.07) and 1.66 (95% confidence interval, 1.02-2.72, P=0.04), respectively. Progression-free survival and overall survival rates at 5 years were 92% and 96%, respectively. Achieving a major molecular response at 1 year was associated with complete absence of progression and a probability of achieving a complete molecular response of 89%. CONCLUSIONS: The addition of intravenous cytarabine to imatinib as upfront therapy for patients with chronic myeloid leukemia is associated with a high rate of complete molecular responses (Clinicaltrials.Gov Identifier: NCT00028847).
BACKGROUND: In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was studied in newly diagnosed patients with chronic myeloid leukemia in the HOVON-51 study. DESIGN AND METHODS: Having reported feasibility previously, we hereby report the efficacy of escalated imatinib (200 mg, 400 mg, 600 mg or 800 mg) in combination with two cycles of intravenous cytarabine (200 mg/m(2) or 1000 mg/m(2) days 1 to 7) in 162 patients with chronic myeloid leukemia. RESULTS: With a median follow-up of 55 months, the 5-year cumulative incidences of complete cytogenetic response, major molecular response, and complete molecular response were 89%, 71%, and 53%, respectively. A higher Sokal risk score was inversely associated with complete cytogenetic response (hazard ratio of 0.63; 95% confidence interval, 0.50-0.79, P<0.001). A higher dose of imatinib and a higher dose of cytarabine were associated with increased complete molecular response with hazard ratios of 1.60 (95% confidence interval, 0.96-2.68, P=0.07) and 1.66 (95% confidence interval, 1.02-2.72, P=0.04), respectively. Progression-free survival and overall survival rates at 5 years were 92% and 96%, respectively. Achieving a major molecular response at 1 year was associated with complete absence of progression and a probability of achieving a complete molecular response of 89%. CONCLUSIONS: The addition of intravenous cytarabine to imatinib as upfront therapy for patients with chronic myeloid leukemia is associated with a high rate of complete molecular responses (Clinicaltrials.Gov Identifier: NCT00028847).
Authors: Susan Branford; John F Seymour; Andrew Grigg; Chris Arthur; Zbigniew Rudzki; Kevin Lynch; Timothy Hughes Journal: Clin Cancer Res Date: 2007-12-01 Impact factor: 12.531
Authors: S Branford; N C P Cross; A Hochhaus; J Radich; G Saglio; J Kaeda; J Goldman; T Hughes Journal: Leukemia Date: 2006-09-14 Impact factor: 11.528
Authors: Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson Journal: N Engl J Med Date: 2006-12-07 Impact factor: 91.245
Authors: Timothy P Hughes; Susan Branford; Deborah L White; John Reynolds; Rachel Koelmeyer; John F Seymour; Kerry Taylor; Chris Arthur; Anthony Schwarer; James Morton; Julian Cooney; Michael F Leahy; Philip Rowlings; John Catalano; Mark Hertzberg; Robin Filshie; Anthony K Mills; Keith Fay; Simon Durrant; Henry Januszewicz; David Joske; Craig Underhill; Scott Dunkley; Kevin Lynch; Andrew Grigg Journal: Blood Date: 2008-09-03 Impact factor: 22.113
Authors: Wendy Deenik; Bronno van der Holt; Gregor E G Verhoef; Willem M Smit; Marie J Kersten; Hanneke C Kluin-Nelemans; Leo F Verdonck; Augustin Ferrant; Anton V M B Schattenberg; Jeroen J W M Janssen; Pieter Sonneveld; Marinus van Marwijk Kooy; Shulamit Wittebol; Roelof Willemze; Pierre W Wijermans; Petra H M Westveer; H Berna Beverloo; Peter Valk; Bob Löwenberg; Gert J Ossenkoppele; Jan J Cornelissen Journal: Blood Date: 2008-01-02 Impact factor: 22.113
Authors: Hugues de Lavallade; Jane F Apperley; Jamshid S Khorashad; Dragana Milojkovic; Alistair G Reid; Marco Bua; Richard Szydlo; Eduardo Olavarria; Jaspal Kaeda; John M Goldman; David Marin Journal: J Clin Oncol Date: 2008-06-02 Impact factor: 44.544
Authors: Richard A Larson; Brian J Druker; Francois Guilhot; Stephen G O'Brien; Gilles J Riviere; Tillmann Krahnke; Insa Gathmann; Yanfeng Wang Journal: Blood Date: 2008-02-06 Impact factor: 22.113